Samil Pharmaceutical Co.,Ltd (KRX:000520)
South Korea · Delayed Price · Currency is KRW 6,200.00
-180.00 (-2.82%)
At close: Aug 21, 2026
KRX:000520 Revenue
Samil Pharmaceutical Co.,Ltd had revenue of 50.60B KRW in the quarter ending June 30, 2026, a decrease of -5.92%. This brings the company's revenue in the last twelve months to 207.33B, down -4.54% year-over-year. In the year 2025, Samil Pharmaceutical Co.,Ltd had annual revenue of 210.25B, down -4.30%.
Revenue (ttm)
207.33B
Revenue Growth
-4.54%
P/S Ratio
0.64
Revenue / Employee
355.62M
Employees
583
Market Cap
132.50B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 210.25B | -9.45B | -4.30% |
| Dec 31, 2024 | 219.70B | 23.35B | 11.89% |
| Dec 31, 2023 | 196.35B | 16.67B | 9.28% |
| Dec 31, 2022 | 179.68B | 45.43B | 33.84% |
| Dec 31, 2021 | 134.25B | 11.25B | 9.14% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Jeil Pharma Holdings | 630.89B |
| HANDOK | 560.89B |
| Jeil Pharmaceutical Co.,Ltd | 543.49B |
| Dongwha Pharm.Co.,Ltd | 513.24B |
| Kyongbo Pharmaceutical | 279.55B |
| Ilyang Pharmaceutical Co.,Ltd | 277.96B |
| Daihan Pharmaceutical | 211.44B |
| Hana Pharm | 139.33B |